BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 26271109)

  • 1. Blood Pressure Levels at the Time of Percutaneous Coronary Revascularization and Risk of Coronary In-Stent Restenosis.
    Tocci G; Barbato E; Coluccia R; Modestino A; Pagliaro B; Mastromarino V; Giovannelli F; Berni A; Volpe M
    Am J Hypertens; 2016 Apr; 29(4):509-18. PubMed ID: 26271109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Everolimus-Eluting Stents in Patients With Bare-Metal and Drug-Eluting In-Stent Restenosis: Results From a Patient-Level Pooled Analysis of the RIBS IV and V Trials.
    Alfonso F; Pérez-Vizcayno MJ; García Del Blanco B; García-Touchard A; López-Mínguez JR; Masotti M; Zueco J; Melgares R; Mainar V; Moreno R; Domínguez A; Sanchís J; Bethencourt A; Moreu J; Cequier A; Martí V; Otaegui I; Bastante T; Gonzalo N; Jiménez-Quevedo P; Cárdenas A; Fernández C;
    Circ Cardiovasc Interv; 2016 Jul; 9(7):. PubMed ID: 27412868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for revascularization and in-stent restenosis in patients with triple-vessel disease after second-generation drug-eluting stent implantation: a retrospective analysis.
    Zeng M; Yan X; Wu W
    BMC Cardiovasc Disord; 2021 Sep; 21(1):446. PubMed ID: 34535088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of everolimus-eluting stents in the treatment of drug-eluting stent versus bare-metal stent restenosis.
    Almalla M; Pross V; Marx N; Hoffmann R
    Coron Artery Dis; 2012 Nov; 23(7):492-6. PubMed ID: 22990414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease.
    Tiroch K; Mehilli J; Byrne RA; Schulz S; Massberg S; Laugwitz KL; Vorpahl M; Seyfarth M; Kastrati A;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):29-36. PubMed ID: 24332416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors of in-stent restenosis among coronary artery disease patients with syphilis undergoing percutaneous coronary intervention: a retrospective study.
    Zhang L; Wang Y; Zhang Z; Liang H; Wu L; Ni L; Gao G; Yang D; Zhao H; Xiao J
    BMC Cardiovasc Disord; 2021 Sep; 21(1):438. PubMed ID: 34525967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The characteristics and risk factors of in-stent restenosis in patients with percutaneous coronary intervention: what can we do.
    Wang P; Qiao H; Wang R; Hou R; Guo J
    BMC Cardiovasc Disord; 2020 Dec; 20(1):510. PubMed ID: 33276720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Clinical Outcomes After Bioresorbable Vascular Scaffold Implantation for the Treatment of Coronary In-Stent Restenosis: A Multicenter Italian Experience.
    Moscarella E; Ielasi A; Granata F; Coscarelli S; Stabile E; Latib A; Cortese B; Tespili M; Tanaka A; Capozzolo C; Caliendo L; Colombo A; Varricchio A
    Circ Cardiovasc Interv; 2016 Apr; 9(4):e003148. PubMed ID: 27059683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical presentation and outcomes of coronary in-stent restenosis across 3-stent generations.
    Magalhaes MA; Minha S; Chen F; Torguson R; Omar AF; Loh JP; Escarcega RO; Lipinski MJ; Baker NC; Kitabata H; Ota H; Suddath WO; Satler LF; Pichard AD; Waksman R
    Circ Cardiovasc Interv; 2014 Dec; 7(6):768-76. PubMed ID: 25466551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coronary CT angiography-derived quantitative markers for predicting in-stent restenosis.
    Tesche C; De Cecco CN; Vliegenthart R; Duguay TM; Stubenrauch AC; Rosenberg RD; Varga-Szemes A; Bayer RR; Yang J; Ebersberger U; Baquet M; Jochheim D; Hoffmann E; Steinberg DH; Chiaramida SA; Schoepf UJ
    J Cardiovasc Comput Tomogr; 2016; 10(5):377-83. PubMed ID: 27431607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3-Year Clinical Follow-Up of the RIBS IV Clinical Trial: A Prospective Randomized Study of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis in Coronary Arteries Previously Treated With Drug-Eluting Stents.
    Alfonso F; Pérez-Vizcayno MJ; Cuesta J; García Del Blanco B; García-Touchard A; López-Mínguez JR; Masotti M; Zueco J; Cequier A; Velázquez M; Moreno R; Mainar V; Domínguez A; Moris C; Molina E; Rivero F; Jiménez-Quevedo P; Gonzalo N; Fernández-Pérez C;
    JACC Cardiovasc Interv; 2018 May; 11(10):981-991. PubMed ID: 29798776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of red blood cell distribution in predicting drug-eluting stent restenosis in patients with stable angina pectoris after coronary stenting.
    Zhao K; Li YJ; Gao S
    Coron Artery Dis; 2015 May; 26(3):220-4. PubMed ID: 25647458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of insulin resistance on in-stent restenosis in patients undergoing coronary drug-eluting stent implantation after long-term angiographic follow-up.
    Zhao LP; Xu WT; Wang L; Li H; Shao CL; Gu HB; Chan SP; Xu HF; Yang XJ
    Coron Artery Dis; 2015 Jan; 26(1):5-10. PubMed ID: 25211654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of clinical presentations, angiographic patterns and outcomes of in-stent restenosis between bare metal stents and drug eluting stents.
    Rathore S; Kinoshita Y; Terashima M; Katoh O; Matsuo H; Tanaka N; Kimura M; Tsuchikane E; Nasu K; Ehara M; Asakura K; Asakura Y; Suzuki T
    EuroIntervention; 2010 Feb; 5(7):841-6. PubMed ID: 20142201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison between drug-coated balloon angioplasty and second-generation drug-eluting stent placement for the treatment of in-stent restenosis after drug-eluting stent implantation.
    Kang IS; Shehata I; Shin DH; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Hong MK
    Heart Vessels; 2016 Sep; 31(9):1405-11. PubMed ID: 26337620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of clinical outcomes of two different types of paclitaxel-coated balloons for treatment of patients with coronary in-stent restenosis.
    Nguyen VPT; Kim C; Hong SJ; Ahn CM; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Hong MK
    Heart Vessels; 2019 Sep; 34(9):1420-1428. PubMed ID: 30903315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of endothelial dysfunction in patients undergoing percutaneous coronary intervention in the era of drug-eluting stents.
    Kubo M; Miyoshi T; Oe H; Ohno Y; Nakamura K; Ito H
    BMC Cardiovasc Disord; 2015 Sep; 15():102. PubMed ID: 26399321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of stent diameter and length on in-stent restenosis after DES vs BMS implantation in patients needing large coronary stents-A clinical and health-economic evaluation.
    Zbinden R; von Felten S; Wein B; Tueller D; Kurz DJ; Reho I; Galatius S; Alber H; Conen D; Pfisterer M; Kaiser C; Eberli FR
    Cardiovasc Ther; 2017 Feb; 35(1):19-25. PubMed ID: 27662632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remnant lipoproteins play an important role of in-stent restenosis in type 2 diabetes undergoing percutaneous coronary intervention: a single-centre observational cohort study.
    Qin Z; Zhou K; Li YP; Wang JL; Cheng WJ; Hu CP; Shi C; He H; Zhou YJ
    Cardiovasc Diabetol; 2019 Jan; 18(1):11. PubMed ID: 30691501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching types of drug-eluting stents does not prevent repeated in-stent restenosis in patients with coronary drug-eluting stent restenosis.
    Nojima Y; Yasuoka Y; Kume K; Adachi H; Hattori S; Matsutera R; Kohama Y; Sasaki T
    Coron Artery Dis; 2014 Dec; 25(8):638-44. PubMed ID: 25076360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.